RecipientAmount (USD million)Deal/Technology HighlightCollaborator / InvestorDeal TypeCountry
Alcon Inc.5,000The planned spinoff would enable both Novartis and Alcon to focus fully on their respective growth strategies and create a world leading eye care devices company. The leading ophthalmology pharmaceuticals business will continue to develop as part of Novartis, with 2017 sales of USD 4.6 billion and the potential blockbuster medicine RTH258 (brolucizumab) in development for neovascular AMD and diabetic macular edema. Novartis AGSpin-offUnited States
Cotiviti Holdings, Inc.4,900The combined business will operate as a private healthcare information technology company with unique, data-driven capabilities. Together, the companies are expected to have greater impact in the healthcare IT market by increasing affordability, reducing waste and improving outcomes and quality as well as offer new opportunities to create substantial value for clients, including complementary solutions across multiple intervention points in the payment process.Verscend Technologies, Inc., Veritas CapitalAcquisitonUnited States
Recordati S. p. A.3,530Recordati has always been a very carefully managed, international pharma company with a broad platform of products and a strong geographical footprint in primary care. Over the last decade Recordati has built up a very attractive rare disease business which we look forward to expanding in addition to the core business. We hope that through our expertise and global healthcare network we will help accelerate this growth across orphan and specialty care to build a global leader in the industry.CVC Capital PartnersAcquisitonItaly
British Patient Capital, Dementia Discovery Fund3,280British Patient Capital will support UK businesses with high growth potential to access the long-term financing that will enable them to grow into world-class businesses. The British Business Bank is launching British Patient Capital, a new £2.5bn programme designed to enable long-term investment in high growth potential companies across the UK led by ambitious entrepreneurs who want to build successful, world-class businesses.British Business BankInvestmentUnited Kingdom
Ethicon, Inc. (Johnson & Johnson)2,700Advanced Sterilization Products (ASP) provides innovative sterilization and disinfection solutions and pioneered low-temperature hydrogen peroxide sterilization technology. ASP’s products, which are sold globally, include the STERRAD system for sterilizing instruments and the EVOTECH and ENDOCLENS systems for endoscope reprocessing and cleaning.Fortive CorporationAcquisitonUnited States
Foundation Medicine, Inc.2,400Together, the companies will leverage expertise in genomics and molecular information to enhance the development of personalised medicines and care for patients with cancer to drive ubiquity of Foundation Medicine’s high quality comprehensive genomic profiling (CGP) testing and innovative data services.RocheAcquisitonUnited States
Zentiva (Sanofi)2,220The signing of this share purchase agreement marks a critical step on the way to the closing of the deal and the transfer of the Zentiva business to Advent, that is anticipated during the course of the fourth quarter of 2018.Advent InternationalAcquisitonFrance
Akebia Therapeutics, Inc.1,300Keryx’s Auryxia® (ferric citrate) is an FDA-approved medicine to treat dialysis dependent CKD patients for hyperphosphatemia and non-dialysis dependent CKD patients for iron deficiency anemia (IDA). Akebia’s vadadustat is an investigational Phase 3 oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) with the potential to advance the treatment of patients with anemia due to CKD, many of whom are currently receiving injectable erythropoietin-stimulating agents (ESAs).Keryx Biopharmaceuticals, Inc.Merger AgreementUnited States
Calico1,000Working together with AbbVie, Calico pursues discovery-stage research and development. AbbVie provides scientific and clinical development support and will lend its commercial expertise to lead future development and commercialization activities. Since 2014, the collaboration between the two companies has produced more than two dozen early-stage programs addressing disease states across oncology and neuroscience and yielded new insights into the biology of aging.AbbVieCollaboration United States
Oxford BioMedica843Axovant Sciences will fund all clinical development costs and manufacturing process development and scale-up activities for AXO-Lenti-PD. The agreement also allows for both parties to put in place a clinical and commercial supply agreement for GMP manufacturing of AXO-Lenti-PD at Oxford BioMedica. Axovant Sciences expects to initiate a Phase I/II dose escalation study of AXO-Lenti-PD in patients with advanced Parkinson’s disease by the end of 2018.Axovant SciencesLicense AgreementUnited Kingdom
Translate Bio805Three-year collaboration focused on developing vaccines for up to five infectious disease pathogens will bring together Sanofi Pasteur’s leadership in vaccines with Translate Bio’s expertise in mRNA research and developmentSanofi PasteurCollaborationUnited States
Samsung Bioepis700Biogen will pay Samsung BioLogics approximately $700 million to increase its ownership in Samsung Bioepis to approximately 49.9%, This option suggests that Biogen, a leader in multiple sclerosis and other neurological disorders, is significantly increasing its interest in biosimilars. Samsung Bioepis focuses on biosimilar development. It has six biosimilar candidates, some of which have been approved for use in Korea, Europe, Australia, Canada, and Brazil. They are biosimilars for Amgen’s EnbrelBiogenOption AgreementSouth Korea
Pfizer Ventures, Pfizer Venture Investments600Pfizer can support a broad array of early neuroscience research and product development opportunities, which are critical in the nascent area of science - Neuroscience Investment Strategy.Pfizer Inc.InvestmentUnited States
Sage Therapeutics575The collaboration with Shionogi is intended to accelerate development of SAGE-217 in key Asian markets and supports Sage’s mission to bring transformational medicines to patients around the worldShionogi & Co., Ltd.CollaborationUnited States
Microbiotica 534Microbiotica will utilise its precision metagenomics microbiome platform to analyse patient samples from clinical trials of Genentech’s investigational IBD medicines, in order to identify microbiome biomarker signatures of drug response, novel IBD drug targets and live bacterial therapeutic products. Microbiotica will receive an undisclosed upfront payment and is eligible to receive research, development and commercialisation milestone payments up to $534 million based on achievement of certain GenentechCollaborationUnited Kingdom
AMAG Pharmaceuticals 530“The divestiture of CBR is an important step as we execute on AMAG’s strategic plan, which includes leveraging our proven expertise in drug development and commercialization to bring innovative products to patients with unmet medical needs,” said William Heiden, president and chief executive officer at AMAGGI PartnerAcquisitonUnited States
Hookipa Biotech AG 400Hookipa and Gilead will jointly research and Hookipa will manufacture arenavirus-based vectors for clinical development by Gilead. The deal expands the relationship between Hookipa and Gilead following Gilead's participation in Hookipa's Series C financing in December 2017.Gilead Sciences, Inc.CollaborationAustria
TMS Co., Ltd.357TMS-007 is designed to restore blood flow following acute stroke, with an extended treatment window versus current standard of care. Biogen to pay $4 million upfront and $18 million upon exercise of the option, plus potential milestones of up to $335 million and royalties. Agreement reinforces Biogen’s commitment to stroke within its acute neurology portfolio, a strategic emerging growth area. Biogen Option AgreementJapan
Advance Medical352Founded in 1999 by Marc Subirats and Carlos Nueno, Advance Medical is a worldwide leader in telemedicine and expert medical opinion services. The acquisition of Advance Medical expands Teladoc’s international footprint, broadens its breadth of medical services and its physician network, and extends the company’s market leadership.TeladocAcquisitonUnited States
Dementia Discovery Fund (DDF)350The fundraising far exceeded its initial target of $200 million (£130 million), making it the first and largest venture fund focused entirely on discovering and developing novel therapies for dementia, including Alzheimer’s disease. The fund is managed by SV Health and was formed through the collaboration of leading pharmaceutical companies (Biogen, Eli Lilly and Company, GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and Takeda), the UK Department of Health and Social Care and the charity AlzheU.K. government’s Department of Health, Alzheimer’s Research UK (ARUK)R&D InvestmentUnited Kingdom
Blueprint Medicines346This is exclusive collaboration and license agreement for the development and commercialization of avapritinib, BLU-554 and BLU-667 in Mainland China, Hong Kong, Macau and Taiwan, either as monotherapies or combination therapies. Discovered and developed by Blueprint Medicines, avapritinib, BLU-554 and BLU-667 are potent and highly selective investigational kinase medicines that have each demonstrated clinical proof-of-concept in genomically defined subsets of patients with cancer.Cstone PharmaceuticalsLicense AgreementUnited States
EPD Solutions292The acquisition will complement Philips’ portfolio of interventional imaging systems, smart catheters, planning and navigation software, and services, and will allow the company to introduce new solutions in the EUR 2+ billion market [2] for image-guided treatment of cardiac arrhythmias, which is growing at a double-digit rate.Royal PhilipsAcquisitonBritish Virgin Islands
Biologicals Development Center 271New Biologicals Development Center in Biberach, Germany bundles biologics development, increases capacity and expands clinical supply network. Increased development capacities reflect research pipeline growth and free up capacity for contract manufacturing and adds to a number of major recent investments into the global Boehringer Ingelheim biopharmaceuticals development network aiming to further increase the company’s mammalian cell culture capabilities.Boehringer IngelheimR&D InvestmentGermany
Tricida, Inc.256The closing of its initial public offering of 13,455,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 1,755,000 shares of common stock for total gross proceeds of approximately $255.6 million.Goldman Sachs & Co.IPOUnited States
Exosome Diagnostics250Exosome Diagnostics markets a urine-based test, ExoDx® Prostate(IntelliScore) (EPI), to assist physicians in determining the need for a prostate biopsy in patients with an ambiguous PSA test result. Exosome Diagnostics has approximately 200 filed patents and applications to protect the technology and enable the development of novel, highly sensitive diagnostics in various pathologies with either difficult or no current diagnostic solutions, like prostate, bladder, kidney, breast, glioblastoma anBio-Techne CorporationAcquisitonUnited States
I-Mab Biopharma220The completion of Series C financing for USD 220 million will be used primarily to advance the pre-clinical and clinical development of ten Best-in-Class investigational drugs in the pipeline.Hillhouse CapitalSeries C FinancingChina
CORD:USE Cord Blood Bank, Inc. 200Cryo-Cell International, Inc. is the world's first private cord blood bank. More than 500,000 parents from 87 countries trust Cryo-Cell to preserve their family members' stem cells. Cryo-Cell's mission is to provide clients with state-of-the-art stem cell cryopreservation services and support the advancement of regenerative medicine. Cryo-Cell operates in a facility that is FDA registered, cGMP-/cGTP-compliant and is licensed in all states requiring licensure.Cryo-Cell International, Inc.AcquisitonUnited States
Deciphera Pharmaceuticals172Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the closing of its previously announced underwritten public offering of 4,300,000 shares of its common stock at a public offering price of $40.00 per share for aggregate gross proceeds of $172 million, before deducting underwriting discounts and commissions and estimated offering expenses.Canaccord Genuity LLCIPOUnited States
Mirati Therapeutics, Inc139Mirati's precision oncology clinical programs utilize next-generation genomic testing to identify and select cancer patients who are most likely to benefit from targeted drug treatment. In immuno-oncology, Mirati is advancing clinical programs where the ability of its product candidates to improve the immune environment of tumor cells may enhance and expand the efficacy of existing immunotherapy medicines when given in combination. Cowen, Barclays and SunTrust Robinson HumphreyIPOUnited States
Forty Seven129Forty Seven has granted the underwriters a 30-day option to purchase up to an additional 1,055,250 shares of common stock solely to cover over-allotments, if any, at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market under the symbol "FTSV" on June 28, 2018.Morgan StanleyIPOUnited States
Aptose Biosciences Inc.125CG-806 is an oral, first-in-class pan-FLT3/pan-BTK multi-kinase inhibitor that represents a potential best-in-class therapeutic for patients with AML. Aptose has been conducting Investigational New Drug (IND) enabling studies with CG-806, as well as numerous preclinical studies. When tested against fresh bone marrow samples from patients with AML, CG-806 demonstrated superior potency and range of activity relative to all other FLT3 inhibitors evaluated.CrystalGenomics, Inc. License AgreementUnited States
Translate Bio115Translate Bio has announced the pricing of its initial public offering of 9,350,000 shares of its common stock at a price to the public of $13.00 per share, for total gross proceeds of approximately $121.6 million.Leerink Partners, CitigroupIPOUnited States
Kadmon Corporation113Proceeds from the offerings will be used for preclinical and clinical development of Kadmon’s lead product candidates, discovery, research and preclinical studies of its other product candidates and for other general corporate purposes.Vivo CapitalIPOUnited States
Precision BioSciences110Precision plans to utilize the proceeds from this financing to accelerate and expand its product portfolio. Specifically, Precision targets taking its lead, off-the-shelf CAR-T product into the clinic while advancing both its lead in vivo gene therapy program into IND-enabling studies and its flagship food program into field trials.Franklin Templeton InvestmentsSeries B FinancingUnited States
Kaleido Biosciences101Kaleido is redefining traditional R&D with its unique discovery and development model that enables product candidates to advance rapidly into the clinic, dramatically reducing time and cost. Abu Dhabi Investment Authority (ADIA)Series C FinancingUnited States
REGENXBIO Inc.100REGENXBIO Receives $100 Million Accelerated License Payment Due to Acquisition of AveXis by NovartisNovartis AGLicense PaymentUnited States
Stealth BioTherapeutics100The proceeds from the financings will be used to initiate a phase 2b clinical trial of Stealth's lead compound, elamipretide, in intermediate dry age-related macular degeneration, for which positive interim results were recently reportedAtlantis Investment ManagementR&D InvestmentUnited States
Eisai Center for Genetics Guided Dementia Discovery100Eisai Co., Ltd. has announced that it has decided to establish the Eisai Center for Genetics Guided Dementia Discovery (“G2D2”), a new exploratory research facility focused on immuno-dementia based on human genetics, aimed at innovative drug discovery in the field of dementia, in Cambridge, Massachusetts, the United States. Using genetic information as a starting point, G2D2 is aiming to control neural inflammation which is a primary cause of dementia along with amyloid beta (A?) and tau, and brEisai Co., Ltd.R&D InvestmentUnited States
Neon Therapeutics100The gross proceeds from the offering were $100.0 million before deducting underwriting discounts and commissions and estimated offering expenses. In addition, the underwriters have a 30-day option to purchase up to 937,500 additional shares of common stock at the initial public offering price less underwriting discounts and commissions. All of the shares in the offering were offered by Neon Therapeutics. Morgan Stanley & Co. LLCIPOUnited States
Xeris Pharmaceuticals86To develop and commercialize ready-to-use injectable and infusible drug formulationsRBC Capital MarketsIPOUnited States
SutroVax85Proceeds of the financing will be used to advance the company’s potentially best-in-class broad-spectrum pneumococcal conjugate vaccine (PCV) candidate through mid-stage clinical development and continue to expand its pipeline of novel vaccines.TPG GrowthSeries C FinancingUnited States
Jazz Pharmaceuticals80Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Defitelio® (defibrotide sodium) and Vyxeos® (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase® and Defitelio® (defibrotide) in countries outside the U.S.TerSera Therapeutics LLCAsset AgreementIreland
Kezar Life Sciences75To advance KZR-616 for the treatment of lupus and lupus nephritis through its KZR-616-002 Phase 1b/2 clinical trial; to advance KZR-616 for the treatment of idiopathic inflammatory myopathies and up to three additional autoimmune indications into Phase 1b or Phase 2 clinical trials; to advance discovery and preclinical development in Kezar's protein secretion program; and the remainder to fund other research and development activities, working capital and other general corporate purposesJefferies GroupIPOUnited States
Evotec AG71Evotec will accelerate the infectious disease research pipeline development and initiate new open innovation R&D initiatives in anti-infectives. The initial focus areas will be on antimicrobial resistance (“AMR”) and superbug infections, Tuberculosis and Malaria, as well as the creation of novel antiviral therapies with new mechanisms of action. SanofiCollaborationGermany
Cibus70The funding will be used to commercialize Cibus’ first commercial product, SU Canola — a non-transgenic (non-GMO) sulfonylurea tolerant weed control crop — and to accelerate research and development of an expanding portfolio of impactful, high-value, non-transgenic crops, including early releases of canola, flax, rice and potato followed by traits in every major crop. In its first two years on the market, SU Canola has sold out of inventory, and experienced triple digit sales growth, with continFidelity ManagementSeries C FinancingUnited States
Metacrine, Inc., 65Metacrine’s lead program is focused on the farnesoid X receptor (FXR). FXR represents a promising target to treat non-alcoholic steatohepatitis (NASH), a debilitating condition that is becoming a leading cause for liver transplant. Proceeds will support clinical development of FXR program in NASH and GI diseases.Venrock Healthcare PartnersSeries C FinancingUnited States
Alpha Biopharma Inc.65The proceeds from this financing will be used to conduct a global multi-center Phase II clinical study of AZD3759, AlphaBio's lead product, as well as expansion of AlphaBio's product pipeline.Qiming Venture PartnersSeries A FinancingChina
Nimbus Therapeutics65“We have made substantial progress across our entire portfolio, including inhibitors of Tyk2 (tyrosine kinase 2) and antagonists of STING (stimulator of interferon genes), both under our immunology alliance with Celgene. Additionally, our wholly owned STING agonist program has generated novel, highly potent, bona fide small molecules with compelling preclinical data.” Tyk2 is an important signal-transduction kinase for key pro-inflammatory cytokine receptors, including IL-23, IL-12 and interferoAtlas VentureFinancingUnited States
Massachusetts Mfg Facility60WuXi Biologics is a leading global platform company providing end-to-end solutions for biologics with a mission to accelerate and transform biologics discovery, development and manufacturing to benefit patients around the world.WuXi BiologicsManufacturing InvestmentUnited States
Skyhawk Therapeutics, Inc.60The collaboration grants Celgene the exclusive option to in-license worldwide intellectual property rights associated with therapeutic candidates for up to five programs with potential utility in the treatment of amyotrophic lateral sclerosis (ALS), Huntington's Disease, and additional neurological disorders.Celgene CorporationCommercialization AgreementUnited States
Pacira Pharmaceuticals, Inc.58The aim of the collaboration is to advance the development and commercialization of EXPAREL® (bupivacaine liposome injectable suspension) in China. Nuance Biotech Co. Ltd License AgreementUnited States
Decibel Therapeutics55The proceeds from the financing will be used to advance Decibel’s clinical and preclinical product candidates as well as to build out its comprehensive hearing drug discovery and development platform and capabilitiesThird Rock VenturesSeries C FinancingUnited States
Carisma Therapeutics53Carisma Therapeutics' discovery and development efforts are focused on their proprietary CAR-Macrophage platform – the first technology to combine antigen recognition with the effector function of macrophages. The proposed dual mechanism of action includes the ability to directly kill targeted cells and the ability to leverage antigen-presenting cell biology to mount an adaptive immune response. AbbVie VenturesSeries A FinancingUnited States
Juvenescence AI50Juvenescence has built an outstanding team of researchers and drug developers, led by Dr Declan Doogan and Dr Annalisa Jenkins. The company’s partnership and licensing model targets projects where Juvenescence holds a significant interest in promising novel technologies, using its world-class team to help to shepherd these therapies towards clinical proof of concept and commercialisation.UndisclosedSeries A FinancingIsle of Man
Quantum Surgical50Quantum Surgical is developing next-generation robotic solutions for minimally invasive cancer therapies. Quantum's predecessor company Medtech SA, a leading French neurosurgical robotics company, was acquired by global orthopaedics giant Zimmer Biomet in 2016 after an investment from ABG in 2015.Ally Bridge GroupSeries A FinancingFrance
Universidade Católica Portuguesa50The Project Consortium aims to explore means of using waste from fermentation to develop new products and applications from co-products. This valorization of co-products is expected to significantly reduce production cost and create additional sustainability in the production process.Amyris, Inc.PartnershipPortugal
Ligand Pharmaceuticals Incorporated47Ligand will continue to be eligible to earn royalties at the same rate and terms as the previous agreement and the pre-defined contract payments have been eliminated. With this new business relationship, WuXi Bio believes it will be able to increase the number of OmniAb antibodies it discovers for its clients in China and around the world.WuXi BiologicsLicense ExpansionUnited States
Enyo Pharma47ENYO Pharma lead candidate, EYP001, is an orally bioavailable small molecule currently being evaluated in phase Ib in patients with chronic hepatitis B. EYP001 is a synthetic non-steroidal, non-bile acid FXR agonist with a very good tolerability profile. Andera Partners Series B FinancingFrance
Verastem Oncology43Verastem Oncology, a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, announced a registered sale to funds of 7,166,666 shares of the Company’s common stock at a price of $6.00 per share. The gross proceeds to Verastem Oncology from the offering are expected to be approximately $43.0 million.Consonance CapitalRegistered Direct OfferingUnited States
Starpharma40Starpharma licenses VivaGel® BV to Mundipharma for Europe, Russia, CIS1 and the balance of Latin America to be marketed as part of the popular BETADINE® Feminine Care portfolioMundipharmaLicense AgreementAustralia
Skyhawk Therapeutics, Inc.40Skyhawk launched earlier this year with a focus on the development of small molecule therapeutics that correct RNA mis-splicing that is typically called "exon skipping." That error occurs when key regions on the RNA are left out during the RNA splicing process. Skyhawk is developing proprietary technology that “enables the rational design of small molecules that target specific binding pocket regions on RNA, using both sequence and structural specificity, at particular moments in the RNA splicAlexandria Venture InvestmentsEquity InvestmentUnited States
Emulate36The proceeds will expand product suite and commercialization of Human Emulation System™ as a comprehensive platform for use across the entire drug discovery and development processFounders FundSeries C FinancingUnited States
Hangzhou Just Biotherapeutics35To enhance R&D capabilities and accelerate clinical trials globally Hillhouse CapitalSeries B FinancingChina
Pharnext SA24The financing consists of three tranches of bonds with an annual interest rate of EURIBOR+11%. The first tranche of €11.5 million will be issued on June 30, 2018 at the latest, the second tranche of €3.5 million will be issued on July 30, 2018 at the latest and the third tranche of €5 million could be issued at Pharnext’s will and following top-line results from Pharnext’s ongoing pivotal Phase 3 trial of PXT3003, its lead drug candidate for the treatment of Charcot-Marie-Tooth disease type 1A (IPF PartnersBond LoanFrance
Broad Institute of MIT and Harvard, Precision Cardiology Laboratory22Research in the newly launched Precision Cardiology Laboratory will bring scientists from both organizations into an integrated work space at the Broad Institute, effectively combining Broad’s innovative methods for basic scientific discovery and the clinical expertise of its practicing physician/researchers with Bayer’s long history of drug development.Bayer AGLaunchUnited States
NBE-Therapeutics20NBE develops next-generation ADCs based on its proprietary site-specific SMAC-conjugationTM technology and a novel ultra-potent anthracycline-based toxin platform with the objective to develop first- and best-in-class ADC product candidates against tumor targets in cancer indications of high, unmet medical need.PPF Capital Partners Fund (PPF)Series B FinancingSwitzerland
Oncologie17Building a pipeline of First and Best-in-Class clinical stage drug candidates through licensing and partnering, Oncologie is leveraging the recent regulatory changes in China to conduct parallel clinical development in China and the US to bring the next wave of Immuno-Oncology products to the two most important markets simultaneously. Oncologie is developing multiple global programs currently in Phase 2 and Phase 3 whose mechanisms are designed to combine with immune checkpoint inhibitors to impPivotal bioVenture Partners Seed FundingChina
Complement Pharma16The aim of this partnership to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative disorders. C6 inhibition prevents the formation of the destructive membrane attack complex (MAC), a complex of terminal complement proteins that mediate cellular injury following complement activation, and has the potential to treat a variety of central nervous system disorders.Alexion PharmaceuticalsPartnershipThe Netherlands
InVivo Therapeutics Holdings Corp.15InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services IncIPOUnited States
Lupin Limited15Through the partnership agreement, Mylan will commercialize Lupin's proposed etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia.Mylan N.V.PartnershipIndia
Nuance Biotech Co. Ltd 15Series B fundraising led by C-Bridge Capital to commercialize high-value pharmaceuticalC-Bridge CapitalSeries B FinancingChina
Benchling15The new funding comes as the company’s ARR skyrocketed 500% and its customer base tripled year-over-year. Today, more than 100,000 scientists across enterprises and academia are using Benchling. Since its last funding round in 2016, Benchling has seen leading pharmaceutical and biotech customers, such as Regeneron Pharmaceuticals, Incyte, Editas Medicine, Agenus, Zymergen, and Obsidian Therapeutics, standardize on its R&D platform.BenchmarkSeries B FinancingUnited States
Agios 12This is an exclusive collaboration and license agreement for the development and commercialization of ivosidenib (TIBSOVO®; AG-120) in Mainland China, Hong Kong, Macau and Taiwan (“Territory”), either as a monotherapy or in combination with other therapies. Discovered and developed by Agios, ivosidenib is an investigational, first-in-class, oral, targeted inhibitor of the mutant isocitrate dehydrogenase-1 (IDH1) enzyme. CStone Pharmaceuticals will be responsible for conducting the development anCStone PharmaceuticalsLicense AgreementUnited States
Recipharm11SERB has in parallel entered into a long term manufacturing agreement with Recipharm for the supply of the product. Recipharm will continue to use its expertise in manufacturing to serve the market with a very important product whereas SERB, who specializes in the area of emergency care, can further develop the market for ThyroSafe®SERB SA DivestmentSweden
argenx10Over the course of the past two years, argenx has been eligible to receive two preclinical milestones of $ 10 million each. The second milestone was achieved for the molecule ARGX-115. ARGX-115 was discovered under argenx’s Innovative Access Program with the de Duve Institute / Université Catholique de Louvain / WELBIO and exclusively licensed under a research and option agreement in 2013.AbbVieMilestone PaymentNetherlands
Karuna Pharmaceuticals, PureTech Health8Trust Award to Advance Karuna’s lead product candidate KarXT (Karuna-Xanomeline-Trospium)Phase 2 Product Candidate for the Treatment of Schizophrenia Wellcome TrustGrants & AwardsUnited States
RSP Systems8The proceeds of this round will be used to fund more extensive clinical trials, allowing RSP Systems to prepare for regulatory approval and market launch with a stand out product that will revolutionize the way diabetes is managed.Jürgen Hambrecht (BASF)Series B FinancingDenmark
Hancock Jaffe Laboratories8Gross proceeds from the IPO amount to $7,500,000 before underwriting discounts and commissions.Network 1 Financial Securities, Inc.IPOUnited States
Processa Pharmaceuticals7The Company intends to use all proceeds from the private placements to fund the research and development (Phase 2 related activities) of its lead product candidate, PCS-499, and for general corporate purposes.UndisclosedPrivate PlacementUnited States
PharmaMar4PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3,000,000 from ChugaiChugaiTerminating License AgreementSpain
Evotec AG4Evotec receives € 3 million payment from Sanofi. This milestone was triggered after Evotec met pre-agreed critical success criteria for a potential manufacturing process for generation of human induced pluripotent stem cell (iPSC)-derived beta cells, including the demonstration of upscaling potential and suitability of the cell product for encapsulated beta cell function in diabetes models. The goal of the collaboration is to develop a beta cell replacement therapy based on beta cells derived frSanofiMilestone PaymentGermany
Winpoint Health LLC2The acquisition of Winpoint Health LLC offers strategic synergies with our HealthDatix Inc. subsidiary, providing a new and unique opportunity for physicians to identify patients eligible for Annual Wellness Visits as well as Chronic Care Management, both of which are reimbursed by Medicare.iGambit, Inc.AcquisitonUnited States
Elucidata Corporation2Elucidata’s tools allow drug discovery scientists to analyze complex datasets and effectively enable drug discovery. PollyTM, the company’s cloud-based data analytics platform, can drastically transform the end-to-end drug discovery process and allow for more rapid data turnaround and analysis.Hyperplane Venture CapitalSeed FundingUnited States
UndisclosedUndisclosedUpsher-Smith will register the products with the U.S. Food and Drug Administration (FDA) and market and distribute them under its own label in thenU.S. upon FDA approval. The partner company will develop and manufacture the product exclusively for Upsher-Smith. Upsher-Smith Laboratories, LLCDistribution AgreementUnited States
UnilabsUndisclosedThe purpose of the collaboration is to expand access to commercialization channels for companion diagnostics in North America and Europe, and accelerate the adoption of companion diagnostics. The companies will use globally harmonized processes to simplify the technical, regulatory and clinical complexities associated with these critical assays. LabCorp DiagnosticsCollaborationSwitzerland
Addario Lung Cancer Medical Institute (ALCMI)UndisclosedThe goal of the study is to use Inivata's highly sensitive InVision analysis to determine the potential role for ctDNA in measuring minimal residual disease in patients following surgical resection in non-small cell lung cancer (NSCLC) to identify those patients who are in need of further therapy, and also to explore the value of ctDNA in monitoring for relapse.Washington University, InivataCollaborationUnited States
Pharmaceutical Product Development, LLCUndisclosedAs part of the collaboration, NeoGenomics will provide a wide range of lab testing services to support PPD® Laboratories’ oncology clinical trial activities in the U.S., Europe and Asia.NeoGenomics Laboratories, Inc.CollaborationUnited States
Nobles Medical Technologies II, Inc.UndisclosedThe company is building a growth strategy with this expansion further into the European Market and The Netherlands is a key territory with the continued growth of PFO closures in Holland. NMT 2 has partnered with one of the top distributors in the region, Angiocare B.V. Angiocare B.V.Sales LaunchThe Netherlands
Nerviano Medical SciencesUndisclosedThe collaboration between Nerviano Medical Sciences and Merck will initially focus on one target and shall encompass two stages. Nerviano Medical Sciences and Merck will first conduct research work in close collaboration with each other and Merck will subsequently further develop, manufacture and commercialize selected collaboration compounds.Merck & Co.CollaborationItaly
Medical Specialties DistributorsUndisclosedMcKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively.McKesson CorporationAcquisitonUnited States
Digital Health NokiaUndisclosedThe sale is part of Nokia's honed focus on becoming a business-to-business and licensing company. We create the technology to connect the world. Powered by the research and innovation of Nokia Bell Labs, we serve communications service providers, governments, large enterprises and consumers, with the industry's most complete, end-to-end portfolio of products, services and licensing.Eric Carreel (Withings)DivestmentFinland
Centurion BioPharma Corporation, UndisclosedCenturion BioPharma's LADR™ (Linker-Activated Drug Release) oncology drug candidates, LADR-7, LADR-8, LADR-9, and LADR-10, were developed by its team of discovery scientists at its German laboratories and are eligible to advance into Investigational New Drug (IND)-enabling studies. Each of the candidates are rationally designed using Centurion BioPharma's novel LADR™ technology, which enables drug compounds to be molecularly bound to albumin in the body's bloodstream and controls its releaseCytRx Corporation, NantCell, IncLaunchUnited States
Veloxis Pharmaceuticals A/SUndisclosedTo Award First Annual ASTS-Veloxis Fellowship in TransplantationAmerican Society of Transplant SurgeonsPartnershipDenmark
Aravive Biologics, Inc.UndisclosedAravive’s lead program is focused on inhibition of the GAS6-AXL signaling axis, which is a known target associated with the growth and proliferation of multiple tumor types. In preclinical studies, GAS6-AXL inhibition has shown activity, whether achieved by a single agent or in combination with a variety of anticancer therapies including radiation therapy, immuno-oncology agents, and drugs that affect DNA replication and repair. Versartis, Inc.Merger AgreementUnited States
Bio2Source CDMOUndisclosedThe Bio2Source initiative is facilitated by GMS Tenshi, a significant strategic investor both in Stelis Biopharma and Oncobiologics Inc. GMS Tenshi, based in Singapore is a joint-venture between Tenshi Life Sciences Private Limited, an India based life sciences company and GMS Holdings, a Jordan based group with diversified assets across the pharmaceutical and biopharmaceutical space.Stelis Biopharma, Oncobiologics, Inc.LaunchUnited States
LG Chem, Ltd.UndisclosedIONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by LG Chem, Ltd. and to further prove the biological activity of the antibodies.IONTAS LimitedCollaborationKorea
Genentech (Roche Group)UndisclosedTESARO and Genentech are also working together to evaluate the combination of ZEJULA and atezolizumab in patients with metastatic bladder cancer as a part of MORPHEUS, Roche's novel cancer immunotherapy development platform. MORPHEUS is a Phase 1b/2 adaptive platform to develop combinations of cancer immunotherapies more rapidly and efficiently. The planned trial will be conducted by Genentech and is expected to begin by the end of 2018. TESARO, Inc.CollaborationUnited States
HPGC Medical Co., Ltd.UndisclosedWize Pharma, Inc., a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that it has signed an exclusive distribution agreement with HPGC Medical Co., Ltd. (HPGC) for the distribution in China by HPGC of a formula known as LO2A, a drug developed for the treatment of dry eye syndrome (DES), and other ophthalmological illnesses, including Conjunctivochalasis (CCH) and Sjögren's syndrome (Sjögren's). Wize Pharma, Inc.Distribution AgreementChina
IONTAS LimitedUndisclosedIONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by LG Chem, Ltd. and to further prove the biological activity of the antibodies.LG Chem, Ltd.CollaborationUnited Kingdom
Genentech (Roche Group)UndisclosedTESARO and Genentech are also working together to evaluate the combination of ZEJULA and atezolizumab in patients with metastatic bladder cancer as a part of MORPHEUS, Roche's novel cancer immunotherapy development platform. MORPHEUS is a Phase 1b/2 adaptive platform to develop combinations of cancer immunotherapies more rapidly and efficiently. The planned trial will be conducted by Genentech and is expected to begin by the end of 2018. TESARO, Inc.CollaborationUnited States
Harbour BioMed UndisclosedCollaboration combines Harbour’s proprietary H2L2 transgenic mouse platform for generating fully human monoclonal antibodies with Wistar’s cancer biology, immunology expertiseThe Wistar InstitutePartnershipThe Netherlands
Harbour BioMed UndisclosedHarbour BioMed announced today that it has licensed its patented H2L2 fully human antibody discovery platform to Celsius Therapeutics, a newly launched company translating single-cell genomic insights into precision therapeutics. The license was issued through Harbour BioMed’s wholly owned subsidiary, Harbour Antibodies BV.Celsius TherapeuticsLicense AgreementThe Netherlands
Chong Kun DangUndisclosedEisai wants Chong Kun Dang to concentrate on sales for clinics, and use its salespersons to focus on large-scale clients such as general hospitals and nursing hospitals.Eisai KoreaDistribution AgreementSouth Korea
MetaSafe ABUndisclosedMetaSafe is especially focusing on clinical phase drug metabolism studies from safety perspective, but also provides services for preclinical stage of drug development. This acquisition will strengthen Admescope's drug metabolism services further to clinical phase projects, as well as gives the benefit of having another high-quality laboratory facility.Admescope LtdAcquisitonSweden
Bio CDMOUndisclosedBio CDMO refers to i) outsourcing of biologic cell line development and production process, etc., and ii) manufacture outsourcing of non-clinical material, clinical material, and commercialized material.Celltrion, Inc.LaunchSouth Korea
Albany Molecular Research Inc. (AMRI) UndisclosedAMRI the development and manufacture of active pharmaceutical ingredients (API) and drug product for Phase I clinical studies. The bulk of AMRI’s work will occur at the company’s Albany, New York, facilities.National Institute of Allergy and Infectious Disease (NIAID)Contract AgreementUnited States
Oklahoma Health Care Authority, Pharmacy Management ConsultantsUndisclosedThe parties intend for initial research projects to use de-identified claims data to gain insights about medication adherence, missed diagnoses, heightened disease risk and other clinical indicators in Oklahoma's SoonerCare population. Disease states of special interest to each participant include autoimmune diseases, bone health/osteoporosis, migraine and oncology care. AmgenCollaborationUnited States
Precision Medical Products, Inc., (PMP)UndisclosedThis acquisition will allow us to significantly strengthen the position of Röchling as a provider of sophisticated medical technology products and implement our growth strategy in the USARöchling Advent Tool & Mold, IncAcquisitonUnited States
Crawford HealthcareUndisclosedWith the acquisition of Crawford, Acelity expands its portfolio of advanced wound dressings (AWD), further strengthening its position as the global leader in advanced wound healingAcelity L.P. IncAcquisitonUnited Kingdom
Harbour Antibodies BV (Harbour BioMed)UndisclosedLakePharma and Harbour Antibodies BV, a Harbour BioMed subsidiary, today announced a technology partnership providing LakePharma the right to utilize Harbour Antibodies' patented, H2L2 transgenic mouse platform in its therapeutic antibody discovery service offerings to clients in pharmaceutical and therapeutic biotechnology companies.LakePharmaPartnershipThe Netherlands
Insilico MedicineUndisclosedThe funding is intended to enhance Insilico Medicine's work in the innovative approaches to the generation of novel molecules using a variety of machine learning and deep learning techniques, as well as to expand a variety of the biomarker discovery initiatives.WuXi AppTec Corporate Venture FundR&D InvestmentUnited States
Sciformix CorporationUndisclosedSciformix’s offerings include post-marketing safety and risk management, clinical development support services, regulatory affairs and operations, technology services, and real-world evidence solutions. The majority of Sciformix’s 1,100 employees are based in Asia, accelerating Covance’s global expansion.Covance (LabCorp)AcquisitonUnited States
Natural Point S.r.l.UndisclosedRecordati announces the acquisition of 100% of the share capital of Natural Point S.r.l., an Italian company, based in Milan, active in the food supplements market. The company realized sales of € 15 million in 2017 and has an excellent profitability profile. The signing and closing of the transaction took place at the same time.RecordatiAcquisitonItaly
HelioMetrics®nUndisclosedPharmacolog AB and HelioMetrics today announced a new partnership that will deliver solutions designed to stop drug diversion and provide safe administration of IV medications for hospitals and pharmacies in the United States.Pharmacolog ABPartnershipUnited States
MEDNAX, Inc.UndisclosedThe ERACS™ program will encompass comprehensive educational and clinical implementation pathways. The overarching goals will be to educate clinical teams, shorten the length of postoperative hospital stays, reduce the use of opioid analgesics and improve postoperative pain control. In addition, MEDNAX and Pacira will monitor a series of clinical quality, safety and value-based performance indicators including: reduced serious maternal and infant morbidity, reduced postoperative nausea and vomitiPacira Pharmaceuticals, Inc.CollaborationUnited States
LEO Pharma A/SUndisclosedThe partnership marks the first step in an alliance to measure soluble biomarkers from the skin surface of atopic dermatitis patients using a non-invasive skin test technology developed by FibroTx in EstoniaFibroTx LLCPartnershipDenmark
Sanofi CMO Business UndisclosedThe acquisition of Sanofi’s manufacturing centre and business located in Holmes Chapel provides Recipharm with a solid platform to take further advantage of the growing respiratory drug market. It also adds additional inhalation commercial drug product manufacturing capabilitiesRecipharm AcquisitonEurope
KAN Research Institute, Inc. (Eisai Co., Ltd.)UndisclosedThis joint research project was selected by the Japan Agency for Medical Research and Development (AMED) for its Cyclic Innovation for Clinical Empowerment (CiCLE) grant program. Believing that creating innovation through industry-academia-government collaboration is an important initiative, Eisai is currently advancing multiple projects, with this project aimed at creating a Japan-originated nucleic acid drug through industry-academia-government collaboration.Japan Agency for Medical Research and Development (AMED), Cyclic Innovation for Clinical Empowerment (CiCLE)R&D InvestmentJapan
Intabio, Inc.UndisclosedIntabio's Blaze™ utilizes a proprietary microchip technology to separate, quantitate, and seamlessly transfer intact biotherapeutic proteins by electrospray into a mass spectrometer for molecular identification. Bruker will provide support for Intabio's development of the hardware and software to integrate the Blaze instrument to a Bruker MS.Bruker CorporationCollaboration United States
K2 BiomedicalUndisclosedThe acquisition will add drug development capabilities to Orion Biotechnology in Europe. K2Biomedical was initially focused on the prevention of Sexually Transmitted Infections (STIs), including HIV. With this acquisition K2Biomedical becomes Orion Biotechnology Poland SP. Z O.O. Orion BiotechnologyAcquisitonPoland
InnovoCommerceUndisclosedThe relationship brings the convenience and security of Exostar's identity and access management platform, leveraged by nearly half of the world’s 20 largest pharmaceutical companies and the Shared Investigator Platform initiative for clinical trials, to InnovoCommerce's investigatorFIRST clinical and safety document exchange portal – providing the life sciences community with unparalleled convenience, while also meeting the need for strict controls, auditing, and security.ExostarPartnershipUnited States
ABS LaboratoriesUndisclosedABS Laboratories specializes in complex assay method development and validation for the quantification of drugs, metabolites and biomarkers in biological samples for preclinical and clinical trials including final regulatory submission. ACM Global Laboratories (Rochester Regional Health)AcquisitonUnited Kingdom
CelegenceUndisclosedThe partnership between ArisGlobal and Celegence also means that life sciences companies can start to leverage the business process-as-a-service (BPaaS) model for Regulatory Affairs operations.ArisGlobalPartnershipUnited States
Precision Medical Products Inc.UndisclosedRöchling Medical Lancaster will join Röchling Medical's other North American operation, New York-based Röchling Medical Rochester, formerly known as Röchling Advent Tool & Mold. The Röchling Medical Division also includes entities in Germany and China.Röchling GroupAcquisitonUnited States
TLVUndisclosedThe agreement allows for reimbursement of ORKAMBI for people with cystic fibrosis who have two copies of the F508del mutation from July 1Vertex Pharmaceuticals IncorporatedAccess AgreementSweden
Translate BioUndisclosedTranslate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that it has launched an initial public offering of 7,700,000 shares of its common stock. CitigroupIPOUnited States
University of AdelaideUndisclosedMicrobiotica will analyse clinical samples from the Adelaide FMT study to identify the specific bacteria which successfully treated the condition. Microbiotica has developed the leading platform for culture-based precision metagenomics, enabling large-scale strain-level characterisation of microbiome profiles linked to patient phenotype.MicrobioticaCollaborationUnited Kingdom
Nichi-IkoUndisclosedDeveloped by YL Biologics, a joint venture between Lupin’s subsidiary Lupin Atlantis Holdings SA (LAHSA) and Yoshindo, the product will be launched by Nichi-Iko after receiving approval from the Pharmaceuticals and Medical Devices Agency (PMDA).Lupin LimitedCommercialization AgreementJapan
TBD BiodiscoveryUndisclosedCollaboration Combines Expertise in Novel Chemical Compound Synthesis with GMP Manufacture in Drug Discovery with the aim to manage the transition of chemical synthesis of novel intermediates from laboratory to bulk scale under GMP standards utilizing Enamine’s know-how and process development expertise.Enamine Ltd.CollaborationEstonia
Kallyope Inc.UndisclosedNovo Nordisk has an option to license exclusive worldwide rights to develop and commercialize up to six products discovered in the collaboration. Kallyope will receive a license fee if Novo Nordisk chooses to exercise an option to a therapeutic discovered and validated in the joint research plan and potential research, development, and sales milestones.Novo Nordisk A/SCollaborationUnited States
MedisafeUndisclosednMedisafe's Medication Management Platform to Increase Adherence, Education and Awareness of Treatments Including Pradaxa® (dabigatran etexilate mesylate)Boehringer IngelheimPartnershipUnited States
Crown Bioscience Inc.UndisclosedCrownBio boasts the world’s largest collection of patient-derived xenograft (PDX) models and is a leading provider of humanized solutions for immuno-oncology drug development. Leveraging these exclusive capabilities, CrownBio will engraft PDX models selected by Pierre Fabre into CD34+ humanized mouse models. These customized, humanized models will be used to accelerate Pierre Fabre’s innovative immuno-oncology drug discovery pipeline.Pierre Fabre Research InstitutePartnershipUnited States
Yiling Wanzhou International Pharmaceuticals (Shijiazhuang Yiling Pharmaceutical Co. Ltd.)UndisclosedThe FDA approved entecavir in 2005 for the treatment of chronic hepatitis B viral (HBV) infection.1 Entecavir is an HBV nucleoside analog reverse transcription inhibitor that interferes with HBV replication. The FDA approved cilostazol in 2006 for the reduction of symptoms of intermittent claudication.2 Cilostazol is a PDE-III inhibitor. Cilostazol inhibits platelet aggregation, improves endothelial cell function, and acts as a vasodilator enabling blood to move more easily through peripheral blCASI PharmaceuticalsContract AgreementUnited States
Syneos HealthUndisclosedThe collaboration will seek to build a centrally managed infrastructure and regulatory research system around physicians and patients, including deploying expert staff and providing the training and regulatory guidance needed to run a trial, removing physician burden and focusing the experience around the patient.Elligo Health ResearchCollaborationUnited States
Molecular Neurobiology Laboratory at the University of Barcelona, Cellular and Molecular Pharmacology Laboratory of the University of FerraraUndisclosedPhytoplant Research S.L. participated in a first-ever pioneering collaborative project to investigate the ability of cannabinoid cannabigerol (CBG), the molecular precursor of ?9-tetrahydrocannabinol (? 9-THC) and cannabidiol (CBD). The study investigated the ability of the above to modulate the affinity and functionality of type-1 and type-2 cannabinoid receptors (CB1 and CB2, respectively) and CB1–CB2 heteroreceptor complexes.Phytoplant Research S.L.Collaboration Spain
Diakonos Research, Ltd.UndisclosedThis new path breaking technology effectively targets and activates the tumor antigen specific CTL-response and is differentiated from peer technologies in its ability to generate durable immunological memory.APAC BiotechLicense AgreementUnited States
Janssen Pharmaceutica NVUndisclosedThe acqusition adds OTC brand Nizoral to Kramer's portfolio. Nizoral is one of the most widely-recognized and highly-trusted brands in therapeutic hair care.Kramer Laboratories, Avista Capital PartnersBrand AcquisitonBelgium
BioCryst Pharmaceuticals, IncUndisclosedThe Phase 3 trial design agreed upon for Japan, APeX-J, is a randomized, placebo-controlled double-blind trial of 24 weeks duration with a 28-week safety extension. Approximately 24 Japanese subjects with HAE will be enrolled. The APeX-J trial design closely follows the design of APeX-2, a Phase 3 clinical trial being conducted in the U.S., Canada and European countries. APeX-J tests the same dose levels of BCX7353 as in APeX-2, 110 mg daily and 150 mg daily, and the endpoints are identical to tPharmaceuticals and Medical Devices Agency (PMDA)Clinical CollaborationUnited Kingdom
Gossamer Bio, IncUndisclosedThe two companies have agreed that the development and commercialization of Aerpio’s HIF-1 alpha stabilizer, AKB-4924, along with other related compounds. AKB-4924 (to be known as GB004) is an investigational hypoxia-inducible factor-1 alpha (HIF-1 alpha) stabilizer in development for IBD. Unlike other HIF stabilizers in clinical development, which stabilize HIF-2 and stimulate erythropoiesis, GB004 preferentially stabilizes HIF-1 alpha, and has profound anti-inflammatory and mucosal wound healiAerpio Pharmaceuticals, Inc. License AgreementUnited States
Tissue Regenix Group plcUndisclosedTissue Regenix has been granted a Human Tissue Authority (HTA) license (The HTA license will initially be used for the import of the CellRight 'BioRinse' portfolio of osteoinductive bone products from the San Antonio, Texas manufacturing facility into the UK.) to import and distribute its' portfolio of Human tissue derived products from the US for use in the UK marketJefferies International LtdDistribution AgreementUnited States
Transcend Nutressential International LtdUndisclosedThis partnership will enable NUTRESSENT to focus on new formulations and applications for natural Astaxanthin which would be exclusive property of NUTRESSENT. Under this collaboration, AstaReal will contribute scientific and technical support to NUTRESSENT in building the science and technology of natural Astaxanthin and various exclusive formulations to the market.AstaRealPartnershipIndia
Synteract UndisclosedAt iCAN, we are dedicated to advancing the health and well-being of children around the world. An important part of that is collaborating with established partners, such as Synteract in the pediatric clinical trials spaceInternational Children’s Advisory Network (iCAN)Collaboration United States
Harbour BioMedUndisclosedFor the development and manufacturing of Harbour’s leading HCAb antibody. The collaboration with WuXi Biologics will support the supply of Harbour’s products for clinical trials under Investigational New Drug (IND) applications in China and worldwide. WuXi BiologicsPartnershipChina
NovartisUndisclosedFGF401 is being evaluated in Phase I/II clinical trials across the U.S., Europe and Asia as a potential new treatment for hepatocellular carcinoma (HCC) and other solid tumors positive for FGFR4 and KLB (klotho beta) expression. EverNov (Everest Medicines), C-Bridge CapitalLicense AgreementSwitzerland
Calibr (Scripps Research)UndisclosedThis collaboration broadens AbbVie's oncology research to access advanced precision medicine technology to expand the development of potentially life-changing treatments for patients with cancer.AbbVieCollaborationUnited States
WCG® (WIRB-Copernicus Group®) Clinical Services DivisionUndisclosedUnder the strategic partnership, WCG and InformedDNA will launch the Center for Genetics and Precision Medicine in Clinical Trials, which will unite InformedDNA’s substantial genetics resources and expertise with WCG’s global network of 550 experts in clinical trial optimization and its proprietary industry Knowledge Base™.InformedDNAClinical CollaborationUnited States
US WorldMeds, LLCUndisclosedValeant and US WorldMeds, LLC together announced that they have entered into an exclusive agreement to co-promote US WorldMeds' LUCEMYRA™ (lofexidine). LUCEMYRA is the first and only non-opioid medication approved by USFDA for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults.Salix Pharmaceuticals (division of Valeant Pharmaceuticals North America LLC ("Salix")Co-Promotion AgreementUnited States
Ascletis BioScience Co., LtdUndisclosedGanovo®, Ascletis' first innovative drug and the first direct-acting anti-viral agent developed by a domestic company in China, The two parties will work closely in distribution networks and end-user services, to prepare for the launch of Ganovo®(danoprevir).CR Pharmaceutical Commercial Group Co., LtdCooperation AgreementChina
Mundipharma GmBHUndisclosedMundipharma has announced the extension of its strategic partnership with Kolon Life Science to market Invossa-K in Saudi Arabia and United Arab Emirates. Invossa-K is an intra-articular injection that is non-surgical treatment option, demonstrating sustained pain reduction and functional improvement of articular joint for two years following a single injection in a US phase II clinical trial and one year in a Korean phase III clinical trial.Kolon Life SciencePartnershipGermany
ArisGlobalUndisclosedAPCER has already been using ARISg™, ArisGlobal's on-premise safety database. The decision to adopt ArisGlobal's Multi-tenant LifeSphere® Safety MultiVigilance is rooted in its cost performance and compliance. APCER's customers will now have a more integrated solution from clinical to post-marketing PVG. APCER Life SciencesPlatform LaunchUnited States
Arcus Biosciences, Inc.UndisclosedThe collaboration will evaluate IPI-549 in combination with AB928, Arcus's dual adenosine receptor antagonist, and AB122, Arcus's anti-PD-1 antibody, as well as IPI-549 in combination with AB928 and chemotherapy in patients with triple negative breast cancer (TNBC) or ovarian cancer in four separate cohorts.Infinity Pharmaceuticals, Inc.Clinical CollaborationUnited States
CR Pharmaceutical Commercial Group Co., Ltd.UndisclosedThe two parties will work closely in distribution networks and end-user services, to prepare for the launch of Ganovo®(danoprevir).Ascletis BioScience Co., Ltd.Cooperation AgreementChina
Amyris, Inc.UndisclosedThe joint venture named as Microbiome JV seeks to combine Amyris’s best-in-class science and technology with BGI’s gene sequencing expertise, data and analytics. The goal will be to develop health products for the Greater China market using natural products including traditional Chinese medicinal ingredients produced with sustainable resources and through Amyris’s proprietary clean fermentation capabilities.BGI GenomicsJoint VentureUnited States
Nektar TherapeuticsUndisclosedThrough this collaboration, IsoPlexis will employ its IsoCode Chip's single-cell functional profiling in collaboration with Nektar Therapeutics to profile the effects of NKTR-214 in both monotherapy and combination immunotherapy in a clinical setting. IsoPlexis' platform has previously highlighted the potential of polyfunctional T cells, those cells secreting multiple cytokines, as a promising correlate to clinical patient outcome in a variety of immunotherapies.IsoPlexis CorporationCollaborationUnited States
TraceLink Inc.,UndisclosedIBI Lorenzini, IBIGEN group, is an Italian-based, family-run pharmaceutical company and contract manufacturing organization (CMO) that was founded over 100 years ago. TraceLink Inc., the World's Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today announced that IBI Lorenzini has selected TraceLink's solutions to ensure compliance with global serialization regulations.IBI LorenziniSupply Chain Compliance AgreementUnited States
AstraZeneca, University of CambridgeUndisclosedThe center will be based around LUMICKS' C-Trap™ optical tweezers-fluorescence microscope, which for the first time enables real-time observation and probing of biomolecular interactions. The approach will be pioneered in several pharmacology and biology assays with the aim of accelerating the discovery of potential new drugs. LUMICKSCollaborationUnited Kingdom
Berkeley Lights, Inc.UndisclosedThrough the collaboration the companies will combine BLI’s antibody discovery platform for B cells with ChemPartner’s expertise in assay development. The Beacon platform is capable of automatically screening thousands of plasma B cells or gene-edited cells, which speeds up a traditionally time-consuming, manual process. ChemPartner Co., Ltd.CollaborationUnited States
Antibióticos de León (ADL Biopharma)UndisclosedAmyris is now expanding its production contract with ADL in order to provide additional, cost-effective manufacturing capability to meet the higher than expected demands from its partners. ADL Biopharma is one of the first CMOs that Amyris has used to successfully produce farnesene.Amyris, Inc.Contract AgreementSpain
Helsinn Therapeutics (U.S.) Inc. UndisclosedHelsinn has worked with Eisai since 2003 on ALOXI®, a trusted anti-emetic for helping adult patients prevent nausea and vomiting, when it happens right away or later (up to five days) with certain chemotherapy medications, and the product has become the preferred treatment in the national guidelines for chemotherapy-induced nausea and vomiting (CINV) in the U.S.Eisai Inc.Distribution AgreementUnited States
PillPackUndisclosedPillPack is a pharmacy designed to provide the best possible customer experience in the U.S. for people who take multiple daily prescriptions. PillPack delivers medications in pre-sorted dose packaging, coordinates refills and renewals, and makes sure shipments are sent on time.Amazon.com Inc.AcquisitonUnited States
Menarini Asia-PacificUndisclosedSingapore based A. Menarini Asia-Pacific Holdings Pte Ltd (“Menarini Asia-Pacific”) and Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”) have signed a multi-year exclusive licensing agreement for Menarini Asia-Pacific to assume the sales, marketing and distribution of the oral, once-daily, direct factor Xa inhibitor, edoxaban (brand name; LIXIANA®), in the Philippines, Malaysia and Singapore, following respective regulatory approvals in those countries.Daiichi SankyoLicense AgreementSingapore
Royal PhilipsUndisclosedPhilips IntelliSite Pathology Solution is the first, and currently the only, digital pathology solution marketed for primary diagnostic use in the US. Through the implementation of the Philips IntelliSite Pathology Solution , LabCorp will incorporate digitized workflows within its anatomic pathology services, which are an integral component of its comprehensive clinical laboratory and end-to-end drug development services.LabCorp DiagnosticsCollaborationUnited States
RedHill Biopharma UndisclosedMytesi® is the fourth product to be promoted by RedHill's gastrointestinal-focused U.S. salesforce, setting the stage for potential U.S. launch of RedHill’s late clinical-stage products, including TALICIA® (RHB-105) for H. pylori infection, with confirmatory Phase III study top-line results expected in Q4/2018Napo Pharmaceuticals (Jaguar Health, Inc.)Co-Promotion AgreementIsrael
Kymab Group LtdUndisclosedUnder this Clinical Trial Collaboration Agreement, Roche will provide its PD-L1 blocking antibody atezolizumab for use in combination with Kymab's lead investigational anti-ICOS antibody therapy KY1044 in Kymab's upcoming Phase I/II clinical studies in patients with advanced solid cancers.F. Hoffmann-La Roche Ltd Clinical CollaborationUnited Kingdom
Prestige BioPharmaUndisclosedThe partnership arrangement includes the exclusive rights for Alvogen to commercialize Hervelous (trastuzumab) in all of its CEE markets, leveraging the company's strong sales and marketing capabilities and experience in successfully bringing new biosimilars to market.AlvogenLicense AgreementSingapore
ProZyme, Inc.UndisclosedProZyme is an industry leading developer and manufacturer of glycan reagents, kits and standards, which are required for efficient sample prep in the analysis of free glycans. Glycans play diverse roles in biotherapeutics, novel drug development, the study of bacterial physiology, and proteomics research.Agilent Technologies Inc.AcquisitonUnited States
HumanCodeUndisclosedIllumina’s personal genomics spinout Helix is expanding its senior commercial leadership team, alongside the acquisition of smartphone application developer HumanCode, adding to its momentum following a planned $200 million venture capital round. HumanCode has previously partnered with Helix, but now its staff will join the company to help build out its end-to-end, customer-facing platforms.Helix BiosciencesAcquisitonCanada
DSM Sinochem PharmaceuticalsUndisclosedDSM Sinochem Pharmaceuticals (“DSP”) develops, produces and sells intermediates, active pharmaceutical ingredients and finished dosage form pharmaceuticals. DSP is a 50/50 Joint Venture of Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, and Sinochem Group, a Fortune 500 enterprise. Bain Capital Private Equity has partnered closely with management teams to provide the strategic resources to companies and works together to create value for its portfolio compaBain Capital Private EquityAcquisitonSingapore
FLAVORx UndisclosedMEDISCA, the industry leader in providing high quality compounding solutions and services to pharmacists worldwide, proudly announced today that through its collaboration with FLAVORx, it will now provide this exclusive product offering to the Canadian market. This agreement is based on a successful three-year collaboration with FLAVORx in the United States, for which MEDISCA holds exclusive distribution rights for the pharmaceutical compounding industry.MEDISCADistribution AgreementUnited States
UndisclosedUndisclosedBoth the parties shall establish a jointly-owned new Israeli entity, which will initially be controlled 50/50 by each of the parties. The new entity will focus on exploring the potential of alleviating the effects of eye disorders and infections using cannabinoids, while reducing use of steroid based products which are currently widely used.Cannabics Pharmaceuticals Inc.Memorandum of UnderstandingIsrael
Consortia HealthUndisclosedConsortia will offer its patients vFit PLUS™ to help enhance vaginal wellness and improve sexual function post Consortia's training program. vFit PLUS is the world's first patented home-use feminine rejuvenation device using red-light (LED) technology.Joylux, Inc.PartnershipUnited States
Peptonic Medical ABUndisclosedPeptonic Medical AB announced today that they have entered a tech transfer agreement with Orion CMO to prepare for the commercial manufacture of VagiVital™ - a product that Peptonic plans to launch in 2018.Orion CorporationDistribution AgreementFinland